cLRT-Mod: An efficient methodology for pharmacometric model-based analysis of longitudinal phase II dose finding studies under model uncertainty

被引:4
|
作者
Buatois, Simon [1 ,2 ]
Ueckert, Sebastian [3 ]
Frey, Nicolas [2 ]
Retout, Sylvie [2 ]
Mentre, France [1 ]
机构
[1] Univ Paris Diderot, INSERM, IAME, UMR 1137, Paris, France
[2] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Pharmaceut Sci, Roche Innovat Ctr Basel, Basel, Switzerland
[3] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden
关键词
dose‐ response; effects model; LRT; MCP‐ Mod; model averaging; nonlinear mixed; MIXED-EFFECTS MODELS; DISEASE PROGRESSION; ALZHEIMERS-DISEASE; SELECTION; TRIALS; TOFOGLIFLOZIN; GLICLAZIDE;
D O I
10.1002/sim.8913
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Within the challenging context of phase II dose-finding trials, longitudinal analyses may increase drug effect detection power compared to an end-of-treatment analysis. This work proposes cLRT-Mod, a pharmacometric adaptation of the MCP-Mod methodology, which allows the use of nonlinear mixed effect models to first detect a dose-response signal and then identify the doses for the confirmatory phase while accounting for model structure uncertainty. The method was evaluated through extensive clinical trial simulations of a hypothetical phase II dose-finding trial using different scenarios and comparing different methods such as MCP-Mod. The results show an increase in power using cLRT with longitudinal data compared to an EOT multiple contrast tests for scenarios with small sample size and weak drug effect while maintaining pre-specifiability of the models prior to data analysis and the nominal type I error. This work shows how model averaging provides better coverage probability of the drug effect in the prediction step, and avoids under-estimation of the size of the confidence interval. Finally, for illustration purpose cLRT-Mod was applied to the analysis of a real phase II dose-finding trial.
引用
收藏
页码:2435 / 2451
页数:17
相关论文
共 34 条
  • [1] Statistical considerations in model-based dose finding for binary responses under model uncertainty
    Yan, Zhiwu
    Yang, Min
    STATISTICS IN MEDICINE, 2024, 43 (12) : 2472 - 2485
  • [2] Model-based dose finding under model uncertainty using general parametric models
    Pinheiro, Jose
    Bornkamp, Bjoern
    Glimm, Ekkehard
    Bretz, Frank
    STATISTICS IN MEDICINE, 2014, 33 (10) : 1646 - 1661
  • [3] Model-Based Bayesian Adaptive Dose-Finding Designs for a Phase II Trial
    Jones, Byron
    Layton, Gary
    Richardson, Helen
    Thomas, Neal
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2011, 3 (02): : 276 - 287
  • [4] Model-based Confidentiality Analysis under Uncertainty
    Hahner, Sebastian
    Bitschi, Tizian
    Walter, Maximilian
    Bure, Tomas
    Hnetynka, Petr
    Heinrich, Robert
    2023 IEEE 20TH INTERNATIONAL CONFERENCE ON SOFTWARE ARCHITECTURE COMPANION, ICSA-C, 2023, : 256 - 263
  • [5] Extended model-based designs for more complex dose-finding studies
    O'Quigley, John
    Conaway, Mark
    STATISTICS IN MEDICINE, 2011, 30 (17) : 2062 - 2069
  • [6] Power and sample size for dose-finding studies with survival endpoints under model uncertainty
    Deng, Qiqi
    Bai, Xiaofei
    Liu, Dacheng
    Roy, Dooti
    Ying, Zhiliang
    Lin, Dan-Yu
    BIOMETRICS, 2019, 75 (01) : 308 - 314
  • [7] Performance analysis method for model-based irrigation strategies under uncertainty
    Mondaca-Duarte, F. D.
    Heinen, M.
    van Mourik, S.
    METHODSX, 2020, 7
  • [8] Practical model-based dose-finding in phase I clinical trials: Methods based on toxicity
    Thall, PF
    Lee, SJ
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (03) : 251 - 261
  • [9] Exploratory Modeling and Analysis, an approach for model-based foresight under deep uncertainty
    Kwakkel, Jan H.
    Pruyt, Erik
    TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE, 2013, 80 (03) : 419 - 431
  • [10] Model-based design of AQUAVAN® injection dose ranging phase II study.
    Gibiansky, E
    Gibiansky, L
    Wang, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P28 - P28